Articles with public access mandates - Vivek Subbiah, MDLearn more
Not available anywhere: 31
Review
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
V Subbiah, U Lassen, E Élez, A Italiano, G Curigliano, M Javle, ...
The Lancet Oncology 21 (9), 1234-1243, 2020
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Review
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
JF Gainor, G Curigliano, DW Kim, DH Lee, B Besse, CS Baik, ...
The lancet oncology 22 (7), 959-969, 2021
Mandates: US National Institutes of Health
Review
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
V Subbiah, MI Hu, LJ Wirth, M Schuler, AS Mansfield, G Curigliano, ...
The lancet Diabetes & endocrinology 9 (8), 491-501, 2021
Mandates: US National Institutes of Health
Review
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial
PY Wen, A Stein, M van den Bent, J De Greve, A Wick, FYFL de Vos, ...
The lancet oncology 23 (1), 53-64, 2022
Mandates: US National Institutes of Health
Review
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, ...
Nature medicine 29 (1), 115-126, 2023
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Review
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
A Friedlaender, V Subbiah, A Russo, GL Banna, U Malapelle, C Rolfo, ...
Nature reviews Clinical oncology 19 (1), 51-69, 2022
Mandates: US National Institutes of Health
Review
Myeloid/lymphoid neoplasms with FGFR1 rearrangement
P Strati, G Tang, DY Duose, S Mallampati, R Luthra, KP Patel, M Hussaini, ...
Leukemia & Lymphoma 59 (7), 1672-1676, 2018
Mandates: US National Institutes of Health
Review
Current update on gallbladder carcinoma
D Ganeshan, A Kambadakone, P Nikolaidis, V Subbiah, IM Subbiah, ...
Abdominal Radiology 46, 2474-2489, 2021
Mandates: US National Institutes of Health
Review
Phase 1 clinical trials for sarcomas: the cutting edge
V Subbiah, R Kurzrock
Current opinion in oncology 23 (4), 352-360, 2011
Mandates: US National Institutes of Health
Review
Accelerated approvals hit the target in precision oncology
V Subbiah, LJ Wirth, R Kurzrock, R Pazdur, JA Beaver, H Singh, ...
Nature medicine 28 (10), 1976-1979, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Review
Neoadjuvant selective RET inhibitor for medullary thyroid cancer: a case series
KJ Contrera, MK Gule-Monroe, MI Hu, ME Cabanillas, NL Busaidy, ...
Thyroid 33 (1), 129-132, 2023
Mandates: US National Institutes of Health
Review
A phase I study of an MPS1 inhibitor (BAY 1217389) in combination with paclitaxel using a novel randomized continual reassessment method for dose escalation
F Atrafi, O Boix, V Subbiah, JR Diamond, SP Chawla, AW Tolcher, ...
Clinical Cancer Research 27 (23), 6366-6375, 2021
Mandates: US Department of Defense, US National Institutes of Health
Review
EZH2 inhibition for epithelioid sarcoma and follicular lymphoma
R Groisberg, V Subbiah
The lancet oncology 21 (11), 1388-1390, 2020
Mandates: US National Institutes of Health
Review
Impact of tissue-agnostic approvals for patients with sarcoma
RC Pestana, JR Beal, A Parkes, N Hamerschlak, V Subbiah
Trends in Cancer 8 (2), 135-144, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Review
Think globally, act locally: globalizing precision oncology
JT Moyers, V Subbiah
Cancer discovery 12 (4), 886-888, 2022
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Review
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody–Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors
M Duca, DWT Lim, V Subbiah, S Takahashi, J Sarantopoulos, A Varga, ...
Molecular cancer therapeutics 21 (4), 625-634, 2022
Mandates: US National Institutes of Health
Review
Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma
JE Maxwell, MK Gule-Monroe, V Subbiah, M Hu, ND Perrier, ...
Surgery 167 (1), 80-86, 2020
Mandates: US National Institutes of Health
Review
Combination therapies for precision oncology: the ultimate whack-a-mole game
R Groisberg, V Subbiah
Clinical Cancer Research 27 (10), 2672-2674, 2021
Mandates: US National Institutes of Health
Review
Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications
RC Pestana, J Roszik, R Groisberg, S Sen, BA Van Tine, AP Conley, ...
Current Problems in Cancer 45 (5), 100794, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Review
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and …
E Fountzilas, E Krishnan, F Janku, S Fu, DD Karp, A Naing, V Subbiah, ...
Cancer chemotherapy and pharmacology 82, 877-885, 2018
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program